Alcon Inc. [NYSE: ALC] revealed that it has finalized the acquisition of Ivantis, Inc. This acquisition is of great importance for the company has Ivantis has earned a strong reputation as a developer of the novel Hydrus Microstent which is a minimally invasive glaucoma surgery (MIGS) device created to reduce eye pressure for open-angle glaucoma victims in relation to cataract surgery.
Alcon believed that this deal will further bolster its global surgical portfolio and help offer a platform for more growth in the glaucoma space. Alcon has accepted Ivantis associates into Alcon and is looking ahead to unveil Hydrus Microstent on a vast, global scale in the near future to help even more patients see magnificently.
In addition, with this purchase, the direct combination of Ivantis associates will make sure the business continuity and associations with existing clients. It also enabled Alcon to commence its future growth plans to introduce Hydrus Microstent to more global markets and give importance to its continuing evidence-based research.
Furthermore, Hydrus Microstent, which is part of a large and increasing market, is currently introduced for the decrease of intraocular pressure in adult patients with severe to moderate primary open-angle glaucoma in relation to cataract surgery in the U.S. On the other hand, the device is introduced for primary open-angle glaucoma in relation to cataract surgery and as an independent procedure in Germany, the U.K, Singapore, Canada, and, Australia.
Alcon is also intending to carry out independent surgery indications for Hydrus Microstent in the U.S. with clinical studies currently ongoing and additional information about potential expansion plans will be presented in the future.